# Harrow, Inc. Common Stock (HROW)

> Harrow, Inc. Common Stock (HROW) trades at $29.52 (+1.48%) as of 7:30:01 PM EST on Nov 17, 2026, +6.65% over the past month. Market cap is $1.09B, with 14.1 days to cover in short interest.

Canonical: https://massive.com/quote/hrow
Data as of: 2026-11-18T00:30:01.436Z (15-minute delayed)
Source: Massive (https://massive.com/docs/llms.txt)

## Price

**$29.52** +0.43 (+1.48%)
At close · 15-minute delayed
Nasdaq · usd

After hours: **$29.00** -0.52 (-1.76%)
As of 7:30:01 PM EST on Nov 17, 2026 · After hours

## Stock performance

How Harrow, Inc. Common Stock (HROW) stock has performed from one day to one year, with its 52-week range.

| Period | Return |
| --- | --- |
| 1D | +1.48% |
| 1W | -2.77% |
| 1M | +6.65% |
| YTD | -39.76% |
| 1Y | -25.70% |
| 52-wk range | $25.76 – $54.85 |

From daily closes through Nov 17, 2026.

## Key statistics

Today's trading snapshot for HROW: day range, open, previous close, volume and market cap.

| Measure | Value |
| --- | --- |
| Day range | $28.75 – $29.74 |
| Open | $29.00 |
| Prev close | $29.09 |
| Volume | 453.46K |
| Market cap | $1.09B |
| Shares out | 37.53M |

## Valuation and profitability ratios

Valuation and profitability ratios for Harrow, Inc. Common Stock: P/E, P/S, P/B, ROE and more.

| Measure | Value |
| --- | --- |
| P/E | — |
| P/S | 3.60 |
| P/B | 37.41 |
| P/FCF | — |
| ROE | -97.6% |
| ROA | -6.4% |
| Debt/Equity | 10.03 |
| Div yield | 0.00% |

As of Nov 16, 2026

## Insider trading

[Harrow, Inc. Common Stock (HROW) insider trading](https://massive.com/quote/hrow/insider-trading.md): open-market Form 4 buys and sells by Harrow, Inc. Common Stock insiders over the last 12 months.

## 8-K filings

Material corporate events Harrow, Inc. Common Stock has disclosed to the SEC on Form 8-K.

- Nov 9, 2026 · Investor presentation
  “Attached as Exhibit 99.3 to this Current Report on Form 8-K is a presentation of the Company that may be used by the management of the Company in connection with its earnings call, at investor conferences, and at meetings describing the Company.”
- Oct 5, 2026 · Acquisition completion
  “On October 1, 2026, the Company completed the acquisition of the Acquired Assets and assumed the Assumed Liabilities (the "Closing"). At the Closing, the Company paid Viatris $30.0 million in cash, funded with cash on hand.”
- Sep 4, 2026 · [Executive officer departure](https://massive.com/quote/sec-filings/8-k/executive-departures.md)
  “Effective September 4, 2026, Randall E. Pollard ceased serving as Chief Accounting Officer and principal accounting officer of Harrow, Inc. (the “Company”).”
- Aug 10, 2026 · Investor presentation
  “Attached as Exhibit 99.3 to this Current Report on Form 8-K is a presentation of the Company that may be used by the management of the Company in connection with its earnings call, at investor conferences, and at meetings describing the Company.”
- Aug 6, 2026 · Acquisition agreement
  “On August 3, 2026, Harrow, Inc. (the "Company") entered into an Asset Purchase Agreement (the "Purchase Agreement") with Viatris Inc. ("Viatris"), pursuant to which the Company agreed to acquire the global rights to TYRVAYA® (varenicline solution) nasal spray 0.03 mg ("TYRVAYA"), a cholinergic agonist indicated for the treatment of the signs and symptoms of dry eye disease (the "Acquisition"). As consideration for the Acquisition, the Company will pay Viatris thirty million dollars ($30,000,000) in cash at the closing of the Acquisition (the "Closing") and has agreed to pay up to an additional seventy million dollars ($70,000,000) in contingent milestone payments.”

## Dividend history and stock splits

Harrow, Inc. Common Stock's recent dividend payments and stock splits.

### Dividends

No recent dividends.

### Splits

- 1-for-5 · Feb 8, 2013

## HROW short interest

How heavily HROW is shorted: shares short, days to cover and average daily volume.

| Measure | Value |
| --- | --- |
| Days to cover | 14.1 |
| Short interest | 7.09M |
| Avg volume | 502.07K |

As of Oct 30, 2026 · reported to FINRA twice monthly.

## HROW news

The latest news and headlines about Harrow, Inc. Common Stock (HROW).

- [Harrow (HROW) Reports Q3 Earnings: What Key Metrics Have to Say](https://www.zacks.com/stock/news/3026852/harrow-hrow-reports-q3-earnings-what-key-metrics-have-to-say?cid=CS-ZC-FT-fundamental_analysis|nfm-3026852) · Zacks Investment Research · Nov 9, 2026 · negative sentiment
- [Harrow (HROW) Q3 Earnings Lag Estimates](https://www.zacks.com/stock/news/3026828/harrow-hrow-q3-earnings-lag-estimates?cid=CS-ZC-FT-fundamental_analysis|yseop_template_4-3026828) · Zacks Investment Research · Nov 9, 2026 · negative sentiment
- [Profound Medical (PROF) Reports Q3 Loss, Beats Revenue Estimates](https://www.zacks.com/stock/news/3025020/profound-medical-prof-reports-q3-loss-beats-revenue-estimates?cid=CS-ZC-FT-fundamental_analysis|yseop_template_4-3025020) · Zacks Investment Research · Nov 5, 2026 · negative sentiment
- [Prelude Therapeutics Incorporated (PRLD) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release](https://www.zacks.com/stock/news/3023069/prelude-therapeutics-incorporated-prld-expected-to-beat-earnings-estimates-what-to-know-ahead-of-q3-release?cid=CS-ZC-FT-fundamental_analysis|yseop_template_9-3023069) · Zacks Investment Research · Nov 4, 2026 · positive sentiment
- [Harrow (HROW) Expected to Beat Earnings Estimates: Should You Buy?](https://www.zacks.com/stock/news/3020638/harrow-hrow-expected-to-beat-earnings-estimates-should-you-buy?cid=CS-ZC-FT-fundamental_analysis|yseop_template_9-3020638) · Zacks Investment Research · Nov 2, 2026 · positive sentiment

## About Harrow, Inc. Common Stock

Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.

| Measure | Value |
| --- | --- |
| Exchange | Nasdaq |
| Market | stocks |
| Type | CS |
| Currency | USD |
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 373 |
| Listed | Apr 30, 2007 |

[Company website](https://www.harrow.com)

## FAQ

### What is the Harrow, Inc. Common Stock (HROW) stock price today?

Harrow, Inc. Common Stock (HROW) is trading at $29.52 (+1.48% on the day) as of 7:30:01 PM EST on Nov 17, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

### What is Harrow, Inc. Common Stock?

Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S.

### What is the short interest in HROW?

As of Oct 30, 2026, HROW has 7.09M shares short and 14.1 days to cover.

### What exchange is HROW listed on?

Harrow, Inc. Common Stock (HROW) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.

## Live data

Prices here are 15-minute delayed. For real-time HROW quotes and the full history behind this page, use the Massive API or MCP server:

- `GET https://api.massive.com/v3/snapshot?ticker.any_of=HROW`

Requests need a Massive API key. API reference for agents: https://massive.com/docs/llms.txt. Connect an AI agent through the Massive MCP server: https://massive.com/docs/ai-tools.

## Related

- [Harrow, Inc. Common Stock (HROW) insider trading](https://massive.com/quote/hrow/insider-trading.md)
- [SEC 8-K events](https://massive.com/quote/sec-filings/8-k.md)
- [Markets overview](https://massive.com/quote/index.md)

Nothing here is investment advice. Data and content are provided for informational purposes under the Massive Terms of Service: https://massive.com/terms
